Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib.

× No keyword cloud information.

6 in total

Review 1. The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.

Authors: Rajesh R Nair; Joel Tolentino; Lori A Hazlehurst
Journal: Biochem Pharmacol Date: 2010-04-09 Impact factor: 5.858

Review 2. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment.

Authors: Bing-Hua Jiang; Ling-Zhi Liu
Journal: Drug Resist Updat Date: 2008-04-28 Impact factor: 18.500

3. Mammalian target of rapamycin inhibitor RAD001 sensitizes endometrial cancer cells to paclitaxel-induced apoptosis via the induction of autophagy.

Authors: Huan Wang; Dandan Li; Xiaomao Li; Xueling Ou; Suiling Liu; Yu Zhang; Jie Ding; Bo Xie
Journal: Oncol Lett Date: 2016-11-02 Impact factor: 2.967

Review 4. Chronic myeloid leukemia stem cells: targeting therapeutic implications.

Authors: Hanieh Mojtahedi; Niloufar Yazdanpanah; Nima Rezaei
Journal: Stem Cell Res Ther Date: 2021-12-18 Impact factor: 6.832

5. Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

Authors: Martin Henkes; Heiko van der Kuip; Walter E Aulitzky
Journal: Ther Clin Risk Manag Date: 2008-02 Impact factor: 2.423

Review 6. Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.

Authors: Michele Massimino; Stefania Stella; Elena Tirrò; Chiara Romano; Maria Stella Pennisi; Adriana Puma; Livia Manzella; Antonino Zanghì; Fabio Stagno; Francesco Di Raimondo; Paolo Vigneri
Journal: Mol Cancer Date: 2018-02-19 Impact factor: 27.401

6 in total